Being part of the conversation: Turning patient engagement to patient centricityAfter three brushes with cancer, Robert Weker understands the patient journey more than many – and he is Share XBeing part of the conversation: Turning patient engagement to patient centricityhttps://pharmaphorum.com/oncology/turning-patient-engagement-to-patient-centricity/
BMS preps filings for leukaemia maintenance therapy CC-486Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine Share XBMS preps filings for leukaemia maintenance therapy CC-486https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/
Genetic test can predict efficacy of chemotherapy in breast cancerResearchers have found that a genetic test can successfully predict whether chemotherapy would be beneficial for patients with Share XGenetic test can predict efficacy of chemotherapy in breast cancerhttps://pharmaphorum.com/news/genetic-test-can-predict-efficacy-of-chemotherapy-in-breast-cancer/
From poison to lifeline – how my views on chemotherapy changed as a cancer patientCancer survivor Brooke Gant tells us about her experiences with chemotherapy. In 2017, I started off being a Share XFrom poison to lifeline – how my views on chemotherapy changed as a cancer patienthttps://pharmaphorum.com/views-analysis-patients/from-poison-to-lifeline-how-my-views-on-chemotherapy-changed-as-a-cancer-patient/
Eye on ESMO: Day Three – Merck & Co. wins big lung cancer battleMerck unveils impressive data on Keytruda, trumping BMS’ Opdivo Share XEye on ESMO: Day Three – Merck & Co. wins big lung cancer battlehttps://pharmaphorum.com/esmo-2016/eye-esmo-day-three-merck-co-wins-big-lung-cancer-battle/